Why GSK picked Sabin to advance its Ebola vaccines

Making good on a recent proposal by GSK’s Rino Rappuoli on how best to develop vaccines, GSK has handed off clinical Ebola and Marburg vaccine candidates to Sabin Vaccine Institute as the pharma looks to partner with

Read the full 373 word article

User Sign In